Jue Pu
Director/Board Member at LEPU BIOPHARMA CO., LTD.
Net worth: 59 M $ as of 2024-05-30
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Eric Rowinsky | M | 67 |
Inspirna, Inc.
 Inspirna, Inc. Pharmaceuticals: MajorHealth Technology Inspirna, Inc. operates as a clinical stage biopharmaceutical company which develops molecule and antibody cancer therapeutics. It provides drugs for melanoma, colorectal and triple-negative breast cancers. The firm identifies novel cancer targets using a microRNA based target discovery platform that enable the identification and validation of novel post-transcriptionally regulated targets. The company was founded by Masoud Tavazoie, Sohail Tavazoie, Shahram Seyedin-Noor and Saeed Tavazoie in 2010 and is headquartered in New York, NY. | 9 years |
| Ambaw Bellete | M | 54 | 1 years | |
| De Min Zhou | M | 58 | 4 years | |
| Ziye Sui | M | - | 4 years | |
| Saeed Tavazoie | M | - |
Inspirna, Inc.
Inspirna, Inc. Pharmaceuticals: MajorHealth Technology Inspirna, Inc. operates as a clinical stage biopharmaceutical company which develops molecule and antibody cancer therapeutics. It provides drugs for melanoma, colorectal and triple-negative breast cancers. The firm identifies novel cancer targets using a microRNA based target discovery platform that enable the identification and validation of novel post-transcriptionally regulated targets. The company was founded by Masoud Tavazoie, Sohail Tavazoie, Shahram Seyedin-Noor and Saeed Tavazoie in 2010 and is headquartered in New York, NY. | 14 years |
| Yun Yi Li | F | 44 | 4 years | |
| Hai Feng Yang | M | 47 | 4 years | |
| Victor Tong | M | 41 | 1 years | |
| Zhong Jie Pu | M | 61 | 6 years | |
| Feng Mao Hua | M | 56 | 3 years | |
| Brian Liu | M | 36 | 2 years | |
| David Mangelsdorf | M | - |
Inspirna, Inc.
Inspirna, Inc. Pharmaceuticals: MajorHealth Technology Inspirna, Inc. operates as a clinical stage biopharmaceutical company which develops molecule and antibody cancer therapeutics. It provides drugs for melanoma, colorectal and triple-negative breast cancers. The firm identifies novel cancer targets using a microRNA based target discovery platform that enable the identification and validation of novel post-transcriptionally regulated targets. The company was founded by Masoud Tavazoie, Sohail Tavazoie, Shahram Seyedin-Noor and Saeed Tavazoie in 2010 and is headquartered in New York, NY. | - |
| peter vlasselaer | M | - |
Inspirna, Inc.
Inspirna, Inc. Pharmaceuticals: MajorHealth Technology Inspirna, Inc. operates as a clinical stage biopharmaceutical company which develops molecule and antibody cancer therapeutics. It provides drugs for melanoma, colorectal and triple-negative breast cancers. The firm identifies novel cancer targets using a microRNA based target discovery platform that enable the identification and validation of novel post-transcriptionally regulated targets. The company was founded by Masoud Tavazoie, Sohail Tavazoie, Shahram Seyedin-Noor and Saeed Tavazoie in 2010 and is headquartered in New York, NY. | 6 years |
| Maggie Geman Li | F | 58 | 4 years | |
| Hu Li | M | 59 | 4 years | |
| Lei Fang | M | 41 | 4 years | |
| Vijay Kasturi | M | 57 | 1 years | |
| Min MIn Qin | M | 66 | 4 years | |
| Tess Hau | F | - |
Stanford University
| 12 years |
| Raymond Camahort | M | 45 |
Inspirna, Inc.
Inspirna, Inc. Pharmaceuticals: MajorHealth Technology Inspirna, Inc. operates as a clinical stage biopharmaceutical company which develops molecule and antibody cancer therapeutics. It provides drugs for melanoma, colorectal and triple-negative breast cancers. The firm identifies novel cancer targets using a microRNA based target discovery platform that enable the identification and validation of novel post-transcriptionally regulated targets. The company was founded by Masoud Tavazoie, Sohail Tavazoie, Shahram Seyedin-Noor and Saeed Tavazoie in 2010 and is headquartered in New York, NY. | 3 years |
| Hongbing Yang | M | 55 | 4 years | |
| Jiwei Wang | M | 37 | 4 years | |
| Nancy T. Chang | M | 74 |
Inspirna, Inc.
Inspirna, Inc. Pharmaceuticals: MajorHealth Technology Inspirna, Inc. operates as a clinical stage biopharmaceutical company which develops molecule and antibody cancer therapeutics. It provides drugs for melanoma, colorectal and triple-negative breast cancers. The firm identifies novel cancer targets using a microRNA based target discovery platform that enable the identification and validation of novel post-transcriptionally regulated targets. The company was founded by Masoud Tavazoie, Sohail Tavazoie, Shahram Seyedin-Noor and Saeed Tavazoie in 2010 and is headquartered in New York, NY. | - |
| Ming Yang | M | 58 | 4 years | |
| Dieter Weinand | M | 63 |
Inspirna, Inc.
Inspirna, Inc. Pharmaceuticals: MajorHealth Technology Inspirna, Inc. operates as a clinical stage biopharmaceutical company which develops molecule and antibody cancer therapeutics. It provides drugs for melanoma, colorectal and triple-negative breast cancers. The firm identifies novel cancer targets using a microRNA based target discovery platform that enable the identification and validation of novel post-transcriptionally regulated targets. The company was founded by Masoud Tavazoie, Sohail Tavazoie, Shahram Seyedin-Noor and Saeed Tavazoie in 2010 and is headquartered in New York, NY. | 3 years |
| Siu Kuen Lai | F | 48 | 3 years | |
| Nilesh Kumar | M | 47 |
Inspirna, Inc.
Inspirna, Inc. Pharmaceuticals: MajorHealth Technology Inspirna, Inc. operates as a clinical stage biopharmaceutical company which develops molecule and antibody cancer therapeutics. It provides drugs for melanoma, colorectal and triple-negative breast cancers. The firm identifies novel cancer targets using a microRNA based target discovery platform that enable the identification and validation of novel post-transcriptionally regulated targets. The company was founded by Masoud Tavazoie, Sohail Tavazoie, Shahram Seyedin-Noor and Saeed Tavazoie in 2010 and is headquartered in New York, NY. | - |
| Yang Xu | M | 57 | 4 years | |
| Usman Azam | M | 55 |
Inspirna, Inc.
Inspirna, Inc. Pharmaceuticals: MajorHealth Technology Inspirna, Inc. operates as a clinical stage biopharmaceutical company which develops molecule and antibody cancer therapeutics. It provides drugs for melanoma, colorectal and triple-negative breast cancers. The firm identifies novel cancer targets using a microRNA based target discovery platform that enable the identification and validation of novel post-transcriptionally regulated targets. The company was founded by Masoud Tavazoie, Sohail Tavazoie, Shahram Seyedin-Noor and Saeed Tavazoie in 2010 and is headquartered in New York, NY. | 1 years |
| Peter van Vlasselaer | M | 64 |
Inspirna, Inc.
Inspirna, Inc. Pharmaceuticals: MajorHealth Technology Inspirna, Inc. operates as a clinical stage biopharmaceutical company which develops molecule and antibody cancer therapeutics. It provides drugs for melanoma, colorectal and triple-negative breast cancers. The firm identifies novel cancer targets using a microRNA based target discovery platform that enable the identification and validation of novel post-transcriptionally regulated targets. The company was founded by Masoud Tavazoie, Sohail Tavazoie, Shahram Seyedin-Noor and Saeed Tavazoie in 2010 and is headquartered in New York, NY. | 6 years |
| Antoine Papiernik | M | 56 |
Inspirna, Inc.
Inspirna, Inc. Pharmaceuticals: MajorHealth Technology Inspirna, Inc. operates as a clinical stage biopharmaceutical company which develops molecule and antibody cancer therapeutics. It provides drugs for melanoma, colorectal and triple-negative breast cancers. The firm identifies novel cancer targets using a microRNA based target discovery platform that enable the identification and validation of novel post-transcriptionally regulated targets. The company was founded by Masoud Tavazoie, Sohail Tavazoie, Shahram Seyedin-Noor and Saeed Tavazoie in 2010 and is headquartered in New York, NY. | - |
| Swapnil Bhargava | M | - | 1 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Masoud Tavazoie | M | - |
Inspirna, Inc.
Inspirna, Inc. Pharmaceuticals: MajorHealth Technology Inspirna, Inc. operates as a clinical stage biopharmaceutical company which develops molecule and antibody cancer therapeutics. It provides drugs for melanoma, colorectal and triple-negative breast cancers. The firm identifies novel cancer targets using a microRNA based target discovery platform that enable the identification and validation of novel post-transcriptionally regulated targets. The company was founded by Masoud Tavazoie, Sohail Tavazoie, Shahram Seyedin-Noor and Saeed Tavazoie in 2010 and is headquartered in New York, NY. | 13 years |
| Steven Kozhimala | M | - |
The Wharton School of the University of Pennsylvania
| 10 years |
| Pranav Gupta | M | - |
The Wharton School of the University of Pennsylvania
| 13 years |
| Peter Moran | M | - |
Stanford University
| 4 years |
| Sahil Bloom | M | - |
Stanford University
| 4 years |
| Emily Janvey | M | - |
The Wharton School of the University of Pennsylvania
| 5 years |
| Yi Peng Li | M | 47 | - | |
| Sapna Tejwani Jethwa | F | - |
The Wharton School of the University of Pennsylvania
| 11 years |
| Raakhe Kapoor Tandon | F | - |
The Wharton School of the University of Pennsylvania
| 5 years |
| Jordan Moelis | M | - |
The Wharton School of the University of Pennsylvania
| 5 years |
| Vandit D. Shah | M | - |
The Wharton School of the University of Pennsylvania
| 3 years |
| David Bard | M | - |
The Wharton School of the University of Pennsylvania
| 12 years |
| Chase Beeler | M | - |
Stanford University
| 5 years |
| Eli Simon | M | - |
The Wharton School of the University of Pennsylvania
| 5 years |
| Greg Kress | M | - |
Stanford University
| 5 years |
| Haomiao Huang | M | - |
Stanford University
| 7 years |
| Samir Malik | M | - |
The Wharton School of the University of Pennsylvania
| 7 years |
| Shirin Bohra | F | - |
The Wharton School of the University of Pennsylvania
| 12 years |
| Edward Segal | M | - |
Stanford University
| 4 years |
| Jennifer Rowland | F | - |
The Wharton School of the University of Pennsylvania
| 5 years |
| Jing Lin | F | - |
The Wharton School of the University of Pennsylvania
| 8 years |
| Rashad Rahman | M | - |
The Wharton School of the University of Pennsylvania
| 15 years |
| Justin Green | M | - |
The Wharton School of the University of Pennsylvania
| 11 years |
| Christine Black | F | - |
The Wharton School of the University of Pennsylvania
| 10 years |
| Neel Murthy | M | - |
Stanford University
| 6 years |
| Eric Sun | M | - |
The Wharton School of the University of Pennsylvania
| 11 years |
| Xiaohan Zhu | M | - |
The Wharton School of the University of Pennsylvania
| 2 years |
| Chao Hong Hu | M | 58 | 4 years | |
| Rama Sekhar | M | - |
The Wharton School of the University of Pennsylvania
| 2 years |
| Sydney Werber | F | - |
The Wharton School of the University of Pennsylvania
| 4 years |
| Kristen Wong | F | - |
Stanford University
| 4 years |
| Steven Finn | M | 38 |
The Wharton School of the University of Pennsylvania
| 4 years |
| Erin Shipley | F | - |
The Wharton School of the University of Pennsylvania
| 4 years |
| Olivia McKelway | F | - |
The Wharton School of the University of Pennsylvania
| 4 years |
| Andrea Himmel | F | - |
The Wharton School of the University of Pennsylvania
| 4 years |
| Boris Treskunov | M | - |
The Wharton School of the University of Pennsylvania
| 4 years |
| Lucas Andreika | M | - |
The Wharton School of the University of Pennsylvania
| 4 years |
| Jennifer Chen Lai | F | - |
The Wharton School of the University of Pennsylvania
| 4 years |
| Daniel Urgelles | M | - |
The Wharton School of the University of Pennsylvania
| 4 years |
| Thomas Colligan | M | 79 |
The Wharton School of the University of Pennsylvania
| 3 years |
| Di Cai | M | - |
The Wharton School of the University of Pennsylvania
| 2 years |
| Patrick Sullivan | M | - |
The Wharton School of the University of Pennsylvania
| 2 years |
| Joshua Beer | M | - |
The Wharton School of the University of Pennsylvania
| 2 years |
| Ankur R. Dharia | M | - |
The Wharton School of the University of Pennsylvania
| 2 years |
| David Choi | M | - |
The Wharton School of the University of Pennsylvania
| 2 years |
| Mike Dauber | M | - |
The Wharton School of the University of Pennsylvania
| 2 years |
| Joel Hwang | M | - |
The Wharton School of the University of Pennsylvania
| 2 years |
| Rami Elghandour | M | 45 |
The Wharton School of the University of Pennsylvania
| 2 years |
| Gregory Mazlin | M | - |
The Wharton School of the University of Pennsylvania
| 4 years |
| Noran Eid | F | - |
The Wharton School of the University of Pennsylvania
| 2 years |
| Preeti Chadha Doshi | F | - |
The Wharton School of the University of Pennsylvania
| 2 years |
| Sam Ensslin | M | - |
The Wharton School of the University of Pennsylvania
| 2 years |
| Alina Costica DiMeglio | F | - |
The Wharton School of the University of Pennsylvania
| 2 years |
| Talal Arij Khan | M | - |
The Wharton School of the University of Pennsylvania
| 4 years |
| Jeffrey Schwartz | M | 45 |
The Wharton School of the University of Pennsylvania
| 2 years |
| Russell Koch | M | - |
The Wharton School of the University of Pennsylvania
| 4 years |
| David Roberts | M | 40 |
The Wharton School of the University of Pennsylvania
| 2 years |
| Jared Lee Marks | M | 35 |
The Wharton School of the University of Pennsylvania
| 4 years |
| Evgeny Rogovoy | M | - |
The Wharton School of the University of Pennsylvania
| 2 years |
| Edward Chung | M | - |
The Wharton School of the University of Pennsylvania
| 2 years |
| Andrew Fohrer | M | - |
The Wharton School of the University of Pennsylvania
| 2 years |
| Liam Localio | M | - |
The Wharton School of the University of Pennsylvania
| 4 years |
| Brooks Powlen | M | - |
The Wharton School of the University of Pennsylvania
| 3 years |
| Joshua Sherman | M | - |
The Wharton School of the University of Pennsylvania
| 4 years |
| Michael Tischler | M | - |
The Wharton School of the University of Pennsylvania
| 4 years |
| Ji Zhang | M | - |
The Wharton School of the University of Pennsylvania
| 2 years |
| Stephanie Yee | F | - |
The Wharton School of the University of Pennsylvania
| 4 years |
| Tami Zakaria | F | - |
The Wharton School of the University of Pennsylvania
| 2 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 83 | 83.00% |
| China | 17 | 17.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Jue Pu
- Personal Network
